CS
SRPT icon

Credit Suisse’s Sarepta Therapeutics SRPT Stock Holding History

Credit Suisse’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-61,100
Closed -$5.5M – 4263
2021
Q4 		$5.5M Buy
61,100
+10,800
+21% +$923K ﹤0.01% 1941
2021
Q3 		$4.65M Sell
50,300
-10,900
-18% -$840K ﹤0.01% 2125
2021
Q2 		$4.76M Sell
61,200
-4,800
-7% -$364K ﹤0.01% 2121
2021
Q1 		$4.92M Buy
66,000
+49,800
+307% +$4.6M ﹤0.01% 2078
2020
Q4 		$2.76M Buy
+16,200
New +$2.4M ﹤0.01% 2586

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Credit Suisse's SRPT Position: Q1 2024 in Review

Credit Suisse increased its Sarepta Therapeutics (SRPT) stake by 5% in Q1 2024, buying an estimated $1.03M and bringing the position to 176,136 shares worth $22.8M. The position accounts for 0.02% of the portfolio, ranked #600.

Credit Suisse first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $80.8M in Q4 2020. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Credit Suisse held 176,136 shares of Sarepta Therapeutics worth $22.8M as of Q1 2024.
  • Credit Suisse bought 8,399 Sarepta Therapeutics shares in Q1 2024, an estimated $1.03M.
  • Sarepta Therapeutics made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #600 holding.
  • Credit Suisse first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Sarepta Therapeutics position peaked at $80.8M in Q4 2020.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.